Since 2021, the Ward 86 Clinic at the University of California, San Francisco (UCSF) has conducted a pilot study on injected CAB/RPV in patients with viremia. The study enrolled 133 patients who received injected CAB/RPV, 57 of whom had viremia. The mean log10 viral load of these 57 patients was 4.21, and the mean CD4 count was 215 cells/mm3. The pilot study targeted patients with significant barriers to taking oral antiretroviral medication. Therefore, most of the participants with viremia were either unstably housed (42%) or unhoused (10%) and half of them were also using stimulants. Almost all the participants in the pilot study had health insurance (Medicaid, Medicare, or both), as the study was conducted in California. Patients who wanted to participate in the study had to verbally commit to coming to the clinic on time for their injections. The injections were scheduled every four weeks, with graduation to every eight weeks if viral suppression was achieved after three months.